medac
Diagnostika



Stathmin (Klon SP49, Kaninchen) – wichtiger Mitoseregulator und multifunktionales Onkoprotein

- **nützlicher Biomarker bei der CIN-Klassifikation/Zervixkarzinom-Diagnostik**[1]: spezifischer für CIN2/3 als **p16**; ähnliche Zunahme der Immunreaktivität basal → intermediär → superfizial bei höhergradigen Läsionen
- **Malignitäts- und Progressionsmarker in div. Tumortypen**[2,3]**(*):** häufig überexprimiert in fortgeschrittenen Stadien der Tumorprogression und in Metastasen
- **Surrogatmarker für die Aktivierung des PI3K/Akt-Pathways**[4-7]
- hohe Stathmin-Expression potenzieller, prädiktiver Marker für die Sensitivität gegenüber Mikrotubuli-wirksamen, zytotoxischen Chemotherapien

- Mikrotubuli-destabilisierendes Onkoprotein (Synonym: Stathmin-1, Op18)
- zentraler Regulator der Mitose und des mitotischen Spindelapparats: induziert durch pro-mitotische/proliferative Stimuli
- v.a. in **proliferierenden** Zellen exprimiert, im Gegensatz zu Ki-67 jedoch auf die **G2/M-Phase** des Zellzyklus beschränkt

(*) Mamma-, Zervix-[1], Ovarial-, Endometrium-, Urothel-, Prostata-, Magen-, Kolorektal-, Kopf- und Hals-, Hepatozelluläre Karzinome, Lungenkarzinome (NSCLC), Gliome, PNET, Medulloblastome, neuroendokrine Tumoren, Mesotheliome, div. Sarkome, Leukämien (ALL, AML) und Lymphome (s. Ref. 2,3).

Bestell-Information Stathmin-1, Klon SP49 (Kaninchen)

verfügbare Größen:	**Kat.-Nr.**
0,1 ml konzentriert	394R-14
0,5 ml konzentriert	394R-15
1,0 ml konzentriert	394R-16
1,0 ml gebrauchsfertig	394R-17
7,0 ml gebrauchsfertig	394R-18
5 Positivkontrollschnitte	394S

Tel. 04103/8006-111

IVD CE

Verfügbar Sep 2013

medac
Gesellschaft für klinische Spezialpräparate mbH • Diagnostika • Theaterstrasse 6 • D-22880 Wedel
Telefon 04103/8006-342 • Fax 04103/8006-359 • www.medac-diagnostika.de • diagnostika@medac.de

Referenzen Stathmin:

1. Howitt B *et al.* Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. Am J Surg Pathol 2013; 37(1): 89-97.
2. Ng DCH, Byrne F. Stathmin and cancer. Cytoskeleton and Human Disease (ed. M Kavallaris), p. 259-284, Springer 2012.
3. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 2011; 15(11): 1249-1266.
4. Karst AM, *et al.* Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011; 123(1): 5-12.
5. Andersen JN, *et al.* Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010; 2(43): 43ra55.
6. Trovik J, *et al.* Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology 2010; 57(4): 641-646.
7. Saal LH, *et al.* Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104(18): 7564-7569.
8. Iancu-Rubin C, Atweh GF. p27Kip1 and stathmin share the stage for the first time. Trends Cell Biol 2005; 15(7): 346-348.
9. Iancu-Rubin C, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004; 93(2): 242-250.
10. Chen J, *et al.* Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2013; 32(10): 1330-1337.
11. Wang R, *et al.* miR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One 2012; 7(10): e46173.
12. Kang W, *et al.* Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012; 7(3): e33919.
13. Trovik J, *et al.* Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011; 17(10): 3368-3377.
14. Wosnitzer MS, *et al.* Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol 2011; 186(5): 2094-2100.
15. Baquero MT, *et al.* Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 2012; 118(19): 4660-4669.
16. Baik SY, *et al.* Identification of stathmin 1 expression induced by Epstein-Barr virus in human B lymphocytes. Cell Prolif 2007; 40(2): 268-281.
17. Sadow PM, *et al.* Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors. Endocr Pathol 2008; 19(2): 97-103.
18. Golouh R, *et al.* The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110(2): 317-326.
19. Xi W, *et al.* Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 2009; 135(6): 837-846.
20. Wang F, *et al.* Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma. J Surg Oncol 2011; 103(7): 704-715.
21. Nakashima D, *et al.* Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer 2006; 118(3): 704-713.
22. Bièche I, *et al.* Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 1998; 78(6): 701-709.
23. Alli E, *et al.* Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26(7): 1003-1012.
24. Alli E, *et al.* Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007; 71: 1233-1240.
25. Misek DE, *et al.* Transforming properties of a Q18E mutation of the microtubule regulator Op18. Cancer Cell 2002; 2(3):217-228.



medac

Gesellschaft für klinische Spezialpräparate mbH • Diagnostika • Theaterstrasse 6 • D-22880 Wedel
Telefon 04103/8006-342 • Fax 04103/8006-359 • www.medac-diagnostika.de • diagnostika@medac.de